{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T12:56:34Z","timestamp":1794660994670,"version":"4.9.1"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T00:00:00Z","timestamp":1745280000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T00:00:00Z","timestamp":1745280000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Science and Technology Fund of Maoming City","award":["220420204551816"],"award-info":[{"award-number":["220420204551816"]}]},{"name":"Guangdong Province Science and Technology Innovation Strategy Special Fund in Maoming City","award":["2021S0028"],"award-info":[{"award-number":["2021S0028"]}]},{"name":"Special Science and Technology Fund of Maoming City","award":["2020KJZX017"],"award-info":[{"award-number":["2020KJZX017"]}]},{"name":"High-level Hospital Construction Research Project of Maoming People\u2019s Hospital","award":["ZX2020026"],"award-info":[{"award-number":["ZX2020026"]}]},{"name":"Double Talent Plan of Maoming People\u2019s Hospital","award":["SY2021001"],"award-info":[{"award-number":["SY2021001"]}]},{"DOI":"10.13039\/501100003453","name":"Natural Science Foundation of Guangdong Province","doi-asserted-by":"crossref","award":["2022A1515011655"],"award-info":[{"award-number":["2022A1515011655"]}],"id":[{"id":"10.13039\/501100003453","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-025-14125-9","type":"journal-article","created":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T10:52:38Z","timestamp":1745319158000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Genomic and clinical characterization of HER2 exon 20 mutations in non-small cell lung cancer: insights from a multicenter study in South China"],"prefix":"10.1186","volume":"25","author":[{"given":"Yating","family":"Hou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingyang","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuoyun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dahai","family":"Mai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingyu","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zichuan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yisheng","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,22]]},"reference":[{"key":"14125_CR1","doi-asserted-by":"publisher","first-page":"15009","DOI":"10.1038\/nrdp.2015.9","volume":"1","author":"C Gridelli","year":"2015","unstructured":"Gridelli C, Rossi A, Carbone DP, Guarize J, Karachaliou N, Mok T, Petrella F, Spaggiari L, Rosell R. Non-small-cell lung cancer. Nat Rev Dis Primers. 2015;1:15009.","journal-title":"Nat Rev Dis Primers"},{"issue":"10299","key":"14125_CR2","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/S0140-6736(21)00312-3","volume":"398","author":"AA Thai","year":"2021","unstructured":"Thai AA, Solomon BJ, Sequist LV, Gainor JF, Heist RS. Lung cancer. Lancet. 2021;398(10299):535\u201354.","journal-title":"Lancet"},{"issue":"10","key":"14125_CR3","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1002\/cac2.12359","volume":"42","author":"P Chen","year":"2022","unstructured":"Chen P, Liu Y, Wen Y, Zhou C. Non-small cell lung cancer in China. Cancer Commun (Lond). 2022;42(10):937\u201370.","journal-title":"Cancer Commun (Lond)"},{"issue":"1","key":"14125_CR4","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s13045-020-00881-7","volume":"13","author":"R Chen","year":"2020","unstructured":"Chen R, Manochakian R, James L, Azzouqa AG, Shi H, Zhang Y, Zhao Y, Zhou K, Lou Y. Emerging therapeutic agents for advanced non-small cell lung cancer. J Hematol Oncol. 2020;13(1):58.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"14125_CR5","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1111\/1759-7714.12168","volume":"6","author":"Y Shi","year":"2015","unstructured":"Shi Y, Sun Y. Medical management of lung cancer: experience in China. Thorac Cancer. 2015;6(1):10\u20136.","journal-title":"Thorac Cancer"},{"key":"14125_CR6","doi-asserted-by":"crossref","unstructured":"Uy NF, Merkhofer CM, Baik CS. HER2 in non-small cell lung cancer: a review of emerging therapies. Cancers (Basel). 2022;14(17).","DOI":"10.3390\/cancers14174155"},{"issue":"6","key":"14125_CR7","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1007\/s40259-022-00556-4","volume":"36","author":"D Brazel","year":"2022","unstructured":"Brazel D, Kroening G, Nagasaka M. Non-small cell lung cancer with EGFR or HER2 exon 20 insertion mutations: diagnosis and treatment options. BioDrugs. 2022;36(6):717\u201329.","journal-title":"BioDrugs"},{"issue":"7","key":"14125_CR8","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.21037\/tlcr-23-98","volume":"12","author":"D Sentana-Lledo","year":"2023","unstructured":"Sentana-Lledo D, Academia E, Viray H, Rangachari D, Kobayashi SS, VanderLaan PA, Costa DB. EGFR exon 20 insertion mutations and ERBB2 mutations in lung cancer: a narrative review on approved targeted therapies from oral kinase inhibitors to antibody-drug conjugates. Transl Lung Cancer Res. 2023;12(7):1590\u2013610.","journal-title":"Transl Lung Cancer Res"},{"issue":"1","key":"14125_CR9","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1038\/s41571-021-00558-1","volume":"19","author":"A Friedlaender","year":"2022","unstructured":"Friedlaender A, Subbiah V, Russo A, Banna GL, Malapelle U, Rolfo C, Addeo A. EGFR and HER2 exon 20 insertions in solid tumours: from biology to treatment. Nat Rev Clin Oncol. 2022;19(1):51\u201369.","journal-title":"Nat Rev Clin Oncol"},{"issue":"3","key":"14125_CR10","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1097\/JTO.0b013e318249e13f","volume":"7","author":"F Cappuzzo","year":"2012","unstructured":"Cappuzzo F, Cho YG, Sacconi A, Al\u00ec G, Siclari O, Incarbone M, Destro A, Terracciano L, Fontanini G, Marchetti A, et al. p95HER2 truncated form in resected non-small cell lung cancer. J Thorac Oncol. 2012;7(3):520\u20137.","journal-title":"J Thorac Oncol"},{"issue":"1","key":"14125_CR11","doi-asserted-by":"publisher","first-page":"100395","DOI":"10.1016\/j.esmoop.2022.100395","volume":"7","author":"S Ren","year":"2022","unstructured":"Ren S, Wang J, Ying J, Mitsudomi T, Lee DH, Wang Z, Chu Q, Mack PC, Cheng Y, Duan J, et al. Consensus for HER2 alterations testing in non-small-cell lung cancer. ESMO Open. 2022;7(1):100395.","journal-title":"ESMO Open"},{"issue":"2","key":"14125_CR12","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/s10585-024-10278-2","volume":"41","author":"N Pourjamal","year":"2024","unstructured":"Pourjamal N, Yazdi N, Halme A, Joncour VL, Laakkonen P, Saharinen P, Joensuu H, Barok M. Comparison of trastuzumab emtansine, trastuzumab deruxtecan, and disitamab vedotin in a multiresistant HER2-positive breast cancer lung metastasis model. Clin Exp Metastasis. 2024;41(2):91\u2013102.","journal-title":"Clin Exp Metastasis"},{"key":"14125_CR13","doi-asserted-by":"publisher","first-page":"102415","DOI":"10.1016\/j.eclinm.2023.102415","volume":"68","author":"Y Wang","year":"2024","unstructured":"Wang Y, Gong J, Wang A, Wei J, Peng Z, Wang X, Zhou J, Qi C, Liu D, Li J, et al. Disitamab vedotin (RC48) plus toripalimab for HER2-expressing advanced gastric or gastroesophageal junction and other solid tumours: a multicentre, open label, dose escalation and expansion phase 1 trial. EClinicalMedicine. 2024;68:102415.","journal-title":"EClinicalMedicine"},{"issue":"7","key":"14125_CR14","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1016\/S1470-2045(23)00215-2","volume":"24","author":"E Van Cutsem","year":"2023","unstructured":"Van Cutsem E, di Bartolomeo M, Smyth E, Chau I, Park H, Siena S, Lonardi S, Wainberg ZA, Ajani J, Chao J, et al. Trastuzumab deruxtecan in patients in the USA and Europe with HER2-positive advanced gastric or gastroesophageal junction cancer with disease progression on or after a trastuzumab-containing regimen (DESTINY-Gastric02): primary and updated analyses from a single-arm, phase 2 study. Lancet Oncol. 2023;24(7):744\u201356.","journal-title":"Lancet Oncol"},{"issue":"25","key":"14125_CR15","doi-asserted-by":"publisher","first-page":"2419","DOI":"10.1056\/NEJMoa2004413","volume":"382","author":"K Shitara","year":"2020","unstructured":"Shitara K, Bang YJ, Iwasa S, Sugimoto N, Ryu MH, Sakai D, Chung HC, Kawakami H, Yabusaki H, Lee J, et al. Trastuzumab deruxtecan in previously treated HER2-positive gastric cancer. N Engl J Med. 2020;382(25):2419\u201330.","journal-title":"N Engl J Med"},{"issue":"8","key":"14125_CR16","doi-asserted-by":"publisher","first-page":"2079","DOI":"10.1038\/s41591-023-02461-x","volume":"29","author":"SM Liu","year":"2023","unstructured":"Liu SM, Tu HY, Wei XW, Yan HH, Dong XR, Cui JW, Zhou Z, Xu CR, Zheng MY, Li YS, et al. First-line pyrotinib in advanced HER2-mutant non-small-cell lung cancer: a patient-centric phase 2 trial. Nat Med. 2023;29(8):2079\u201386.","journal-title":"Nat Med"},{"issue":"7","key":"14125_CR17","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1200\/JCO.21.01113","volume":"40","author":"YY Elamin","year":"2022","unstructured":"Elamin YY, Robichaux JP, Carter BW, Altan M, Gibbons DL, Fossella FV, Lam VK, Patel AB, Negrao MV, Le X, et al. Poziotinib for patients with HER2 exon 20 mutant non-small-cell lung cancer: results from a phase II trial. J Clin Oncol. 2022;40(7):702\u20139.","journal-title":"J Clin Oncol"},{"issue":"8","key":"14125_CR18","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1016\/j.jtho.2023.03.016","volume":"18","author":"R Cornelissen","year":"2023","unstructured":"Cornelissen R, Prelaj A, Sun S, Baik C, Wollner M, Haura EB, Mamdani H, Riess JW, Cappuzzo F, Garassino MC, et al. Poziotinib in treatment-naive NSCLC harboring HER2 exon 20 mutations: ZENITH20-4, A multicenter, multicohort, open-label, phase 2 trial (Cohort 4). J Thorac Oncol. 2023;18(8):1031\u201341.","journal-title":"J Thorac Oncol"},{"key":"14125_CR19","doi-asserted-by":"publisher","first-page":"1099304","DOI":"10.3389\/fonc.2022.1099304","volume":"12","author":"X Wu","year":"2022","unstructured":"Wu X, Chau YF, Bai H, Zhuang X, Wang J, Duan J. Progress on neoadjuvant immunotherapy in resectable non-small cell lung cancer and potential biomarkers. Front Oncol. 2022;12:1099304.","journal-title":"Front Oncol"},{"issue":"7","key":"14125_CR20","doi-asserted-by":"publisher","first-page":"e196879","DOI":"10.1001\/jamanetworkopen.2019.6879","volume":"2","author":"Y Yu","year":"2019","unstructured":"Yu Y, Zeng D, Ou Q, Liu S, Li A, Chen Y, Lin D, Gao Q, Zhou H, Liao W, et al. Association of survival and immune-related biomarkers with immunotherapy in patients with non-small cell lung cancer: a meta-analysis and individual patient-level analysis. JAMA Netw Open. 2019;2(7):e196879.","journal-title":"JAMA Netw Open"},{"issue":"4","key":"14125_CR21","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.21037\/tlcr-19-664","volume":"9","author":"B Zhang","year":"2020","unstructured":"Zhang B, Zhang L, Yue D, Li C, Zhang H, Ye J, Gao L, Zhao X, Chen C, Huo Y, et al. Genomic characteristics in Chinese non-small cell lung cancer patients and its value in prediction of postoperative prognosis. Transl Lung Cancer Res. 2020;9(4):1187\u2013201.","journal-title":"Transl Lung Cancer Res"},{"issue":"19","key":"14125_CR22","doi-asserted-by":"publisher","first-page":"2811","DOI":"10.1093\/bioinformatics\/btu393","volume":"30","author":"Z Gu","year":"2014","unstructured":"Gu Z, Gu L, Eils R, Schlesner M, Brors B. Circlize implements and enhances circular visualization in R. Bioinformatics. 2014;30(19):2811\u20132.","journal-title":"Bioinformatics"},{"issue":"40","key":"14125_CR23","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.21105\/joss.01317","volume":"4","author":"C Davidson-Pilon","year":"2019","unstructured":"Davidson-Pilon C. Lifelines: survival analysis in python. J Open Source Softw. 2019;4(40):1317.","journal-title":"J Open Source Softw"},{"issue":"3","key":"14125_CR24","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1016\/j.jtho.2015.10.025","volume":"11","author":"BT Li","year":"2016","unstructured":"Li BT, Ross DS, Aisner DL, Chaft JE, Hsu M, Kako SL, Kris MG, Varella-Garcia M, Arcila ME. HER2 amplification and HER2 mutation are distinct molecular targets in lung cancers. J Thorac Oncol. 2016;11(3):414\u20139.","journal-title":"J Thorac Oncol"},{"issue":"1","key":"14125_CR25","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.lungcan.2012.09.018","volume":"79","author":"H Li","year":"2013","unstructured":"Li H, Pan Y, Li Y, Li C, Wang R, Hu H, Zhang Y, Ye T, Wang L, Shen L, et al. Frequency of well-identified oncogenic driver mutations in lung adenocarcinoma of smokers varies with histological subtypes and graduated smoking dose. Lung Cancer. 2013;79(1):8\u201313.","journal-title":"Lung Cancer"},{"issue":"2","key":"14125_CR26","first-page":"84","volume":"3","author":"S Peters","year":"2014","unstructured":"Peters S, Zimmermann S. Targeted therapy in NSCLC driven by HER2 insertions. Transl Lung Cancer Res. 2014;3(2):84\u20138.","journal-title":"Transl Lung Cancer Res"},{"issue":"2","key":"14125_CR27","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1007\/s12013-012-9384-8","volume":"64","author":"S Ren","year":"2012","unstructured":"Ren S, Kuang P, Zheng L, Su C, Li J, Li B, Chen X, Wang Y, KimCurran V, Liu L, et al. Analysis of driver mutations in female non-smoker Asian patients with pulmonary adenocarcinoma. Cell Biochem Biophys. 2012;64(2):155\u201360.","journal-title":"Cell Biochem Biophys"},{"issue":"30","key":"14125_CR28","doi-asserted-by":"publisher","first-page":"4616","DOI":"10.1200\/JCO.2010.29.6038","volume":"28","author":"Y Sun","year":"2010","unstructured":"Sun Y, Ren Y, Fang Z, Li C, Fang R, Gao B, Han X, Tian W, Pao W, Chen H, et al. Lung adenocarcinoma from East Asian never-smokers is a disease largely defined by targetable oncogenic mutant kinases. J Clin Oncol. 2010;28(30):4616\u201320.","journal-title":"J Clin Oncol"},{"issue":"33","key":"14125_CR29","doi-asserted-by":"publisher","first-page":"34300","DOI":"10.18632\/oncotarget.5549","volume":"6","author":"R Wang","year":"2015","unstructured":"Wang R, Zhang Y, Pan Y, Li Y, Hu H, Cai D, Li H, Ye T, Luo X, Zhang Y, et al. Comprehensive investigation of oncogenic driver mutations in Chinese non-small cell lung cancer patients. Oncotarget. 2015;6(33):34300\u20138.","journal-title":"Oncotarget"},{"issue":"Suppl 3","key":"14125_CR30","doi-asserted-by":"publisher","first-page":"S1284","DOI":"10.1245\/s10434-015-4640-y","volume":"22","author":"D Zheng","year":"2015","unstructured":"Zheng D, Wang R, Pan Y, Zheng S, Zhang Y, Li H, Cheng C, Gong R, Li Y, Shen X, et al. Prevalence and clinicopathological characteristics of BRAF mutations in Chinese patients with lung adenocarcinoma. Ann Surg Oncol. 2015;22(Suppl 3):S1284\u20131291.","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"14125_CR31","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/s41698-024-00720-9","volume":"8","author":"L Hong","year":"2024","unstructured":"Hong L, Patel S, Drusbosky LM, Xiong Y, Chen R, Geng R, Heeke S, Nilsson M, Wu J, Heymach JV, et al. Molecular landscape of ERBB2 alterations in 3000 advanced NSCLC patients. NPJ Precis Oncol. 2024;8(1):217.","journal-title":"NPJ Precis Oncol"},{"issue":"18","key":"14125_CR32","doi-asserted-by":"publisher","first-page":"4910","DOI":"10.1158\/1078-0432.CCR-12-0912","volume":"18","author":"ME Arcila","year":"2012","unstructured":"Arcila ME, Chaft JE, Nafa K, Roy-Chowdhuri S, Lau C, Zaidinski M, Paik PK, Zakowski MF, Kris MG, Ladanyi M. Prevalence, clinicopathologic associations, and molecular spectrum of ERBB2 (HER2) tyrosine kinase mutations in lung adenocarcinomas. Clin Cancer Res. 2012;18(18):4910\u20138.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"14125_CR33","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1097\/JTO.0b013e318234f0a2","volume":"7","author":"C Li","year":"2012","unstructured":"Li C, Sun Y, Fang R, Han X, Luo X, Wang R, Pan Y, Hu H, Zhang Y, Pao W, et al. Lung adenocarcinomas with HER2-activating mutations are associated with distinct clinical features and HER2\/EGFR copy number gains. J Thorac Oncol. 2012;7(1):85\u20139.","journal-title":"J Thorac Oncol"},{"issue":"16","key":"14125_CR34","doi-asserted-by":"publisher","first-page":"1997","DOI":"10.1200\/JCO.2012.45.6095","volume":"31","author":"J Mazi\u00e8res","year":"2013","unstructured":"Mazi\u00e8res J, Peters S, Lepage B, Cortot AB, Barlesi F, Beau-Faller M, Besse B, Blons H, Mansuet-Lupo A, Urban T, et al. Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives. J Clin Oncol. 2013;31(16):1997\u20132003.","journal-title":"J Clin Oncol"},{"issue":"21","key":"14125_CR35","doi-asserted-by":"publisher","first-page":"4099","DOI":"10.1002\/cncr.30869","volume":"123","author":"RN Pillai","year":"2017","unstructured":"Pillai RN, Behera M, Berry LD, Rossi MR, Kris MG, Johnson BE, Bunn PA, Ramalingam SS, Khuri FR. HER2 mutations in lung adenocarcinomas: a report from the lung cancer mutation consortium. Cancer. 2017;123(21):4099\u2013105.","journal-title":"Cancer"},{"issue":"7008","key":"14125_CR36","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1038\/431525b","volume":"431","author":"P Stephens","year":"2004","unstructured":"Stephens P, Hunter C, Bignell G, Edkins S, Davies H, Teague J, Stevens C, O\u2019Meara S, Smith R, Parker A, et al. Lung cancer: intragenic ERBB2 kinase mutations in tumours. Nature. 2004;431(7008):525\u20136.","journal-title":"Nature"},{"key":"14125_CR37","doi-asserted-by":"publisher","first-page":"1163485","DOI":"10.3389\/fonc.2023.1163485","volume":"13","author":"RR Sompallae","year":"2023","unstructured":"Sompallae RR, Dundar B, Guseva NV, Bossler AD, Ma D. EGFR and ERBB2 exon 20 insertion\/duplication in advanced non-small cell lung cancer: genomic profiling and clinicopathologic features. Front Oncol. 2023;13:1163485.","journal-title":"Front Oncol"},{"key":"14125_CR38","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.ejca.2022.05.009","volume":"171","author":"JM van Berge Henegouwen","year":"2022","unstructured":"van Berge Henegouwen JM, Jebbink M, Hoes LR, van der Wijngaart H, Zeverijn LJ, van der Velden DL, Roepman P, de Leng WWJ, Jansen AML, van Werkhoven E, et al. Trastuzumab and pertuzumab combination therapy for advanced pre-treated HER2 exon 20-mutated non-small cell lung cancer. Eur J Cancer. 2022;171:114\u201323.","journal-title":"Eur J Cancer"},{"issue":"2","key":"14125_CR39","doi-asserted-by":"publisher","first-page":"488","DOI":"10.4143\/crt.2022.359","volume":"55","author":"BC Ahn","year":"2023","unstructured":"Ahn BC, Han YJ, Kim HR, Hong MH, Cho BC, Lim SM. Real world characteristics and clinical outcomes of HER2-mutant non-small cell lung cancer patients detected by next-generation sequencing. Cancer Res Treat. 2023;55(2):488\u201397.","journal-title":"Cancer Res Treat"},{"key":"14125_CR40","doi-asserted-by":"publisher","first-page":"102605","DOI":"10.1016\/j.ctrv.2023.102605","volume":"120","author":"Q Bai","year":"2023","unstructured":"Bai Q, Wang J, Zhou X. EGFR exon20 insertion mutations in non-small cell lung cancer: clinical implications and recent advances in targeted therapies. Cancer Treat Rev. 2023;120:102605.","journal-title":"Cancer Treat Rev"},{"issue":"22","key":"14125_CR41","doi-asserted-by":"publisher","first-page":"5007","DOI":"10.1200\/JCO.2005.09.111","volume":"23","author":"F Cappuzzo","year":"2005","unstructured":"Cappuzzo F, Varella-Garcia M, Shigematsu H, Domenichini I, Bartolini S, Ceresoli GL, Rossi E, Ludovini V, Gregorc V, Toschi L, et al. Increased HER2 gene copy number is associated with response to gefitinib therapy in epidermal growth factor receptor-positive non-small-cell lung cancer patients. J Clin Oncol. 2005;23(22):5007\u201318.","journal-title":"J Clin Oncol"},{"issue":"11","key":"14125_CR42","doi-asserted-by":"publisher","first-page":"5625","DOI":"10.21873\/anticanres.15378","volume":"41","author":"J Skrickova","year":"2021","unstructured":"Skrickova J, Pesek M, Opalka P, Koubkova L, Zemanova M, Hrnciarik M, Blazek J, Svaton M, Krejci J, Coupkova H, et al. Prognostic value of EGFR Exon-20 insertions in Czech patients with advanced non-small cell lung cancer. Anticancer Res. 2021;41(11):5625\u201334.","journal-title":"Anticancer Res"},{"issue":"1","key":"14125_CR43","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1002\/ijc.30047","volume":"139","author":"M Yang","year":"2016","unstructured":"Yang M, Xu X, Cai J, Ning J, Wery JP, Li QX. NSCLC harboring EGFR exon-20 insertions after the regulatory C-helix of kinase domain responds poorly to known EGFR inhibitors. Int J Cancer. 2016;139(1):171\u20136.","journal-title":"Int J Cancer"},{"key":"14125_CR44","doi-asserted-by":"publisher","first-page":"949304","DOI":"10.3389\/fonc.2022.949304","volume":"12","author":"C Shi","year":"2022","unstructured":"Shi C, Xing R, Li M, Feng J, Sun R, Wei B, Guo Y, Ma J, Wang H. Real-world clinical treatment outcomes in Chinese non-small cell lung cancer with EGFR exon 20 insertion mutations. Front Oncol. 2022;12:949304.","journal-title":"Front Oncol"},{"key":"14125_CR45","doi-asserted-by":"crossref","unstructured":"von Elm E, Altman Dg Fau -, Egger M, Egger M, Fau - Pocock SJ, Pocock Sj Fau - G\u00f8tzsche PC, G\u00f8tzsche Pc Fau - Vandenbroucke JP, Vandenbroucke JP. Strengthening the reporting of observational studies in epidemiology (STROBE). Bmj. 2007;335(7624):806\u2013808.","DOI":"10.1136\/bmj.39335.541782.AD"},{"issue":"11","key":"14125_CR46","doi-asserted-by":"publisher","first-page":"e012799","DOI":"10.1136\/bmjopen-2016-012799","volume":"6","author":"JF Cohen","year":"2016","unstructured":"Cohen JF, Korevaar DA, Altman DG, Bruns DE, Gatsonis CA, Hooft L, Irwig L, Levine D, Reitsma JB, de Vet HC, et al. STARD 2015 guidelines for reporting diagnostic accuracy studies: explanation and. BMJ Open. 2016;6(11):e012799. LID\u2013\u2009012710.011136\/bmjopen-012016-012799 [doi] LID - e012799.","journal-title":"BMJ Open"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-14125-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-025-14125-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-14125-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T11:03:52Z","timestamp":1745319832000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-025-14125-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,22]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["14125"],"URL":"https:\/\/doi.org\/10.1186\/s12885-025-14125-9","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,22]]},"assertion":[{"value":"5 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This prospective observational study was approved by the Ethics Committee of Maoming People\u2019s Hospital (No. PJ2020MI-021-01) and conducted according to the Declaration of Helsinki at Maoming People\u2019s Hospital, the First Affiliated Hospital of Guangzhou Medical University, and the Affiliated Cancer Hospital & Institute of Guangzhou Medical University. The study protocol complied faithfully with the Strengthening the Reporting of Observational Studies in Epidemiology [] and the Standards for Reporting Diagnostic Accuracy criteria []. All participants provided their written informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"752"}}